Higher baseline uric acid concentration is associated with non-attainment of optimal blood pressure.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
05
2020
accepted:
08
07
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
25
9
2020
Statut:
epublish
Résumé
A significant relationship exists between elevated uric acid concentration and both prevalent and incident hypertension; however, data regarding the influence of higher uric acid concentration at baseline on blood pressure control by antihypertensive drugs is scarce. Thus, a prospective cohort study was performed. The study outcome was the non-attainment of optimal blood pressure (NOBP). NOBP level was defined according to the Japanese hypertension guideline. This study enrolled a Japanese community-based cohort (N = 8,664; age 65.5 ± 6.4 years; women, 55.0%) who were not using antihypertensive drugs on the first visit for a health check-up program but started using antihypertensive drug(s) on the next-year visit. The participants were classified into quartiles based basic uric acid concentration. Odds ratios (ORs) were calculated for NOBP as the primary outcome measure. Multivariable logistic analysis showed that quartile 4 was significantly associated with NOBP when quartile 1 was set as the reference (OR (95% confidence interval), 1.36 (1.16-1.59), p<0.01), adjusted for potential confounders, such as age, sex, body mass index, presence of diabetes/dyslipidemia/chronic kidney disease (CKD), history of cardiovascular disease, daily drinking, and current smoking. In the subgroup analysis of female participants and participants with diabetes and CKD, a significant association was observed between +1 mg/dL of uric acid and NOBP. Higher uric acid concentration at baseline was significantly associated with NOBP on the first use of antihypertensive drug(s).
Identifiants
pubmed: 32716977
doi: 10.1371/journal.pone.0236602
pii: PONE-D-20-14313
pmc: PMC7384644
doi:
Substances chimiques
Antihypertensive Agents
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236602Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Kidney Int. 2004 Oct;66(4):1465-70
pubmed: 15458439
Ann Intern Med. 2001 Nov 6;135(9):825-34
pubmed: 11694107
Sci Rep. 2019 Jun 3;9(1):8210
pubmed: 31160664
Diabetes Care. 2011 Jan;34 Suppl 1:S62-9
pubmed: 21193628
Am J Physiol Renal Physiol. 2002 Jun;282(6):F991-7
pubmed: 11997315
Med Sci Monit. 2017 Feb 13;23:790-795
pubmed: 28190873
Hypertens Res. 2015 Mar;38(3):213-8
pubmed: 25374311
Hypertension. 2008 Jun;51(6):1403-19
pubmed: 18391085
Hypertens Res. 2014 Aug;37(8):785-9
pubmed: 24671018
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Sci Rep. 2019 Feb 26;9(1):2813
pubmed: 30808962
Hypertension. 2017 Feb;69(2):228-235
pubmed: 27956574
Medicine (Baltimore). 2018 Feb;97(6):e9765
pubmed: 29419669
Hypertens Res. 2017 Mar;40(3):259-263
pubmed: 27760998
Hypertens Res. 2006 Aug;29 Suppl:S1-105
pubmed: 17366911
Hypertens Res. 2013 Jan;36(1):43-9
pubmed: 22951520
J Hum Hypertens. 2006 Dec;20(12):937-45
pubmed: 17024135
Hypertens Res. 2017 Jun;40(6):620-624
pubmed: 28202946
Kidney Blood Press Res. 2015;40(3):315-22
pubmed: 26067715
Kidney Int. 2005 May;67(5):1739-42
pubmed: 15840020
JAMA. 2008 Aug 27;300(8):924-32
pubmed: 18728266
Int J Cardiol. 2018 Dec 1;272:308-313
pubmed: 29895425
Sci Rep. 2019 Jun 21;9(1):9061
pubmed: 31227765
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Rev Diabet Stud. 2018 Winter;14(4):354-363
pubmed: 29590228
PLoS One. 2014 Dec 01;9(12):e114259
pubmed: 25437867
J Clin Hypertens (Greenwich). 2016 Jan;18(1):53-9
pubmed: 26212524
Hypertension. 2005 Jan;45(1):28-33
pubmed: 15569852